Free Trial

McKesson (MCK) Competitors

McKesson logo
$692.43 -1.55 (-0.22%)
Closing price 04/15/2025 03:59 PM Eastern
Extended Trading
$688.49 -3.94 (-0.57%)
As of 04/15/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MCK vs. COR, CAH, HSIC, PDCO, OMI, HLF, NUS, COSM, HWH, and MEDS

Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Henry Schein (HSIC), Patterson Companies (PDCO), Owens & Minor (OMI), Herbalife (HLF), Nu Skin Enterprises (NUS), Cosmos Health (COSM), HWH International (HWH), and TRxADE HEALTH (MEDS).

McKesson vs.

McKesson (NYSE:MCK) and Cencora (NYSE:COR) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

In the previous week, McKesson had 28 more articles in the media than Cencora. MarketBeat recorded 59 mentions for McKesson and 31 mentions for Cencora. Cencora's average media sentiment score of 1.42 beat McKesson's score of 1.39 indicating that Cencora is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
McKesson
47 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cencora
25 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

85.1% of McKesson shares are held by institutional investors. Comparatively, 97.5% of Cencora shares are held by institutional investors. 0.1% of McKesson shares are held by insiders. Comparatively, 10.8% of Cencora shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

McKesson has a net margin of 0.82% compared to Cencora's net margin of 0.46%. Cencora's return on equity of 328.62% beat McKesson's return on equity.

Company Net Margins Return on Equity Return on Assets
McKesson0.82% -181.26% 5.34%
Cencora 0.46%328.62%4.23%

McKesson has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Cencora has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.

McKesson presently has a consensus target price of $668.50, indicating a potential downside of 3.46%. Cencora has a consensus target price of $284.20, indicating a potential downside of 0.07%. Given Cencora's higher possible upside, analysts plainly believe Cencora is more favorable than McKesson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
McKesson
0 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.88
Cencora
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

McKesson pays an annual dividend of $2.84 per share and has a dividend yield of 0.4%. Cencora pays an annual dividend of $2.20 per share and has a dividend yield of 0.8%. McKesson pays out 13.0% of its earnings in the form of a dividend. Cencora pays out 31.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. McKesson has raised its dividend for 17 consecutive years and Cencora has raised its dividend for 15 consecutive years.

McKesson received 228 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.20% of users gave McKesson an outperform vote while only 65.24% of users gave Cencora an outperform vote.

CompanyUnderperformOutperform
McKessonOutperform Votes
975
74.20%
Underperform Votes
339
25.80%
CencoraOutperform Votes
747
65.24%
Underperform Votes
398
34.76%

McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
McKesson$344.58B0.25$3.00B$21.8431.70
Cencora$638.56M86.37$1.51B$7.0340.46

Summary

McKesson beats Cencora on 13 of the 22 factors compared between the two stocks.

Remove Ads
Get McKesson News Delivered to You Automatically

Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MCK vs. The Competition

MetricMcKessonDrugs, proprietaries, & sundries IndustryMedical SectorNYSE Exchange
Market Cap$86.78B$20.95B$5.33B$18.51B
Dividend Yield0.42%1.57%5.11%4.24%
P/E Ratio31.7011.8121.7331.15
Price / Sales0.259.46379.1425.69
Price / Cash18.3812.9538.1517.53
Price / Book-32.0932.146.464.29
Net Income$3.00B$785.39M$3.20B$1.02B
7 Day Performance6.06%2.40%6.54%6.59%
1 Month Performance6.37%-11.32%-8.55%-6.88%
1 Year Performance32.48%-15.07%10.33%1.23%

McKesson Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MCK
McKesson
4.5845 of 5 stars
$692.43
-0.2%
$668.50
-3.5%
+32.5%$86.78B$344.58B31.7075,000Positive News
COR
Cencora
4.2019 of 5 stars
$284.36
+0.0%
$284.20
-0.1%
+21.4%$55.14B$638.56M40.4542,000Positive News
CAH
Cardinal Health
4.6234 of 5 stars
$134.22
+1.9%
$140.86
+4.9%
+25.4%$32.42B$222.28B25.0446,500Short Interest ↓
Positive News
HSIC
Henry Schein
4.0339 of 5 stars
$65.27
+1.3%
$81.10
+24.3%
-9.1%$8.11B$12.67B26.8622,000Analyst Revision
News Coverage
Gap Down
PDCO
Patterson Companies
3.3581 of 5 stars
$31.32
+1.3%
$26.57
-15.2%
+23.6%$2.77B$6.51B18.327,700Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
High Trading Volume
OMI
Owens & Minor
4.7945 of 5 stars
$6.93
+0.4%
$13.75
+98.4%
-73.4%$535.38M$10.70B-10.6622,500Positive News
HLF
Herbalife
4.4023 of 5 stars
$6.67
-0.3%
$12.00
+79.9%
-20.8%$675.94M$4.99B2.6810,100Positive News
NUS
Nu Skin Enterprises
3.5582 of 5 stars
$6.01
-3.5%
$6.88
+14.4%
-50.5%$298.84M$1.73B-2.0413,400News Coverage
Positive News
COSM
Cosmos Health
1.7912 of 5 stars
$0.36
-2.4%
N/A-47.3%$8.30M$56.04M-0.15100
HWH
HWH International
N/A$1.12
-0.9%
N/A-80.3%$7.25M$1.25M0.00N/AShort Interest ↑
Gap Down
MEDS
TRxADE HEALTH
N/A$0.78
-4.3%
N/A-87.9%$1.10M$7.45M0.0050
Remove Ads

Related Companies and Tools


This page (NYSE:MCK) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners